CoChat

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Open access
Flynn, J, Jones, J, Johnson, A J, Andritsos, L, Maddocks, K, Jaglowski, S, Hessler, J, Grever, M R, Im, E, Zhou, H, Zhu, Y, Zhang, D, Small, K, Bannerji, R, Byrd, J C · 2015 · Leukemia
Cited by 120

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Dinaciclib (SCH727965) is a selective CDKi chosen for clinical development based upon a favorable therapeutic index in cancer xenograft models. We performed a phase I dose escalation study of dinaciclib in relapsed and refractory chronic lymphocytic leukemia (CLL) patients with intact organ function and WBC<200 × 109 /l. Five separate dose levels (5 mg/m2, 7 mg/m2, 10 mg/m2, 14 mg/m2 and 17 mg/m2) were explored dosing on a weekly schedule × 3 with 1 week off (4-week cycles) using a standard 3+3 design with expansion cohorts to optimize safety. Fifty-two patients were enrolled with relapsed and refractory CLL. Escalation through cohorts occurred with two dose-limiting toxicity (DLTs) at the 17 mg/m2 dose (tumor lysis syndrome (TLS) and pneumonia). The phase II expansion occurred at 14 mg/m2 with 16 patients receiving this dose with one DLT (TLS). Additional stepped up dosing to the maximum tolerated dose was examined in 19 patients at this dose. Adverse events included cytopenias, transient laboratory abnormalities and TLS. Responses occurred in 28 (54%) of patients independent of del(17)(p13.1) with a median progression-free survival of 481 days. Dinaciclib is clinically active in relapsed CLL including those patients with high risk del(17)(p13.1) disease and warrants future study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2015.31

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 120

Metadata

Authors
Flynn, J., Jones, J., Johnson, A. J., Andritsos, L., Maddocks, K., Jaglowski, S., Hessler, J., Grever, M. R., Im, E., Zhou, H., Zhu, Y., Zhang, D., Small, K., Bannerji, R., & Byrd, J. C.
Venue
Leukemia
Published
2015-02-24
Volume
29
Issue
7
Pages
1524-1529
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2103580937
Cited by
120
References
2
FWCI
8.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1038/leu.2015.31
The paper
Flynn, J., Jones, J., Johnson, A. J., Andritsos, L., Maddocks, K., Jaglowski, S., Hessler, J., Grever, M. R., Im, E., Zhou, H., Zhu, Y., Zhang, D., Small, K., Bannerji, R., & Byrd, J. C. (2015). Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. https://doi.org/10.1038/leu.2015.31

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.